AUTL

Autolus TherapeuticsB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$2.40

+37.1% vs current

Most likely

Base case

45%

Probability

Target price

$1.60

-8.6% vs current

B-

Bear case

30%

Probability

Target price

$0.80

-54.3% vs current

AI sentiment snapshot

Latest data as of 2026-04-29

AI commentary

Primary evidence quality is decent for a low-coverage biotech because recent SEC filings are available, but forward visibility is still limited and most of the thesis remains a monitoring view around launch execution and binary data. AUTL was at $1.41 at 21:35 UTC on April 29, 2026, down 5.4% from the prior close on the day of the restructuring 8-K, which suggests the market treated the update cautiously even with guidance maintained. Analyst revision data are unavailable in the packet, so the post-filing read-through should be treated as tentative rather than a confirmed sentiment inflection.

RankAlpha Sentiment Codex - 2026-04-29

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-30catalystQ3 2026 completion of workforce reduction is the nearest execution checkHigh impact

Autolus said its board approved an operational-efficiency plan that eliminates about 13% of the workforce, inclusive of actions begun in 2H25, with roughly $8 million of total charges and completion expected by Q3 2026. Management also reaffirmed 2026 AUCATZYL net product revenue guidance, so the near-term test is whether spending falls without disrupting launch or development execution [#8-K-2026-04-29].

2026-12-31event2026 AUCATZYL revenue delivery remains the core operating catalystHigh impact

The 10-K reported $74.3 million of 2025 net product revenue, a U.K. launch under routine NHS commissioning, and no expected EU sales in 2026, while the April 29, 2026 8-K reaffirmed full-year 2026 AUCATZYL net product revenue guidance of $120 million to $135 million. Hitting that guide would help validate launch scaling, but the revenue base is still concentrated in one product [#10-K-2026-03-27][#8-K-2026-04-29].

2026-12-31catalystEnd-2026 BOBCAT data is the clearest pipeline optionality eventHigh impact

Autolus disclosed that first patients were dosed in October 2025 in the BOBCAT Phase 1 dose-escalation study in progressive multiple sclerosis, with initial data expected at the end of 2026. A constructive readout could expand the obe-cel story beyond adult B-ALL, but this is still an early, binary biotech catalyst [#10-K-2026-03-27].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-29 • Updated nightlySource: Internal modelMethodology